AbCellera Begins Phase 2 Trial for ABCL635, Focusing on Menopause Symptoms and Closing Valuation Gap

AbCellera Biologics has begun Phase 2 trials of ABCL635, a non-hormonal treatment for menopause symptoms. This marks a new stage in clinical development and adds a menopause-focused program to the company's pipeline. The Phase 2 start highlights AbCellera's efforts to translate its discovery capabilities into specific, high-impact conditions. Investors will watch for clinical readouts and how the program shapes the company's profile.